| Field | Specification |
|---|---|
| Target | |
| Alternative names | Basic domain helix loop helix protein class B 6; Basic domain helix loop helix protein class B6; BHLH B6; BHLHB 6; bHLHb6; bHLHe21; Class B basic helix-loop-helix protein 6; Class E basic helix-loop-helix protein 21; Olig 1; Olig1; OLIG1_HUMAN; Oligo 1; Oligo1; Oligodendrocyte lineage transcription factor 1; Oligodendrocyte specific bHLH transcription factor 1; Oligodendrocyte transcription factor 1 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | Recombinant Human Oligodendrocyte transcription factor 1 protein (17-105AA) |
| Conjugate | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Purification | |
| Form | Liquid |
| Storage | |
| Storage buffer | |
| Catalog no. (Mfr.) | |
| Main SKU |
Overview
This polyclonal anti-OLIG1 antibody raised in Rabbit, conjugated with FITC. Designed to detect OLIG1 in Human for neuroscience research.
Key elements and design rationale
- Immunogen: Recombinant Human Oligodendrocyte transcription factor 1 protein (17-105AA) — determines epitope; confirm sample prep compatibility.
- Host (Rabbit): Requires anti-rabbit-IgG secondary matching isotype IgG.
- Polyclonal: Multiple epitopes = robust signal; lot-to-lot variability — include controls.
- Isotype (IgG): Match secondary, Protein A/G, and isotype controls to IgG.
- Purification (Protein G purification): Enriches Ig classes; reduces non-specific background.
- FITC: Direct fluorescence (Ex490/Em525); protect from light; use antifade.
Biological background
OLIG1 (also: Basic domain helix loop helix protein class B 6, Basic domain helix loop helix protein class B6, BHLH B6, BHLHB 6, bHLHb6, bHLHe21, Class B basic helix-loop-helix protein 6, Class E basic helix-loop-helix protein 21, Olig 1, Olig1, OLIG1_HUMAN, Oligo 1, Oligo1, Oligodendrocyte lineage transcription factor 1, Oligodendrocyte specific bHLH transcription factor 1, Oligodendrocyte transcription factor 1) — studied in Human systems. Expression, localization, and PTMs vary across cell types and disease states. Consult UniProt, NCBI Gene, and primary literature for current OLIG1 annotation relevant to neuroscience.
Common research applications
- Refer to product documentation for confirmed application data.
Notes for experimental interpretation
- Isotype controls: IgG from Rabbit at equivalent concentration.
- Cross-reactivity: Polyclonal: validate with KO/KD controls.
- Matrix effects: Verify dilution linearity in your sample matrix.
- Reactivity: Confirmed for Human; extrapolation requires validation.
This product is a polyclonal antibody purified from rabbit antiserum.
OLIG1 is a protein studied in Human biology. This polyclonal antibody raised in Rabbit detects OLIG1 in immunoassay applications, IgG isotype.
Reported reactive against Human. Immunogen from Human. Cross-reactivity with untested species requires empirical confirmation.
Application data not specified. Consult datasheet or contact BioHippo support.
FITC (Ex490/Em525): direct fluorescence; protect from light; use antifade for sections.
(1) Isotype control: IgG from Rabbit; (2) Positive control: lysate/cell line expressing OLIG1; (3) Negative control: siRNA KD or KO; (4) Dilution linearity in your sample matrix.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
